The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 15, 2009
Filed:
May. 13, 2002
Lloyd J. Old, New York, NY (US);
Terrance Grant Johns, Melbourne, AU;
Con Panousis, Melbourne, AU;
Andrew Mark Scott, Kew, AU;
Christoph Renner, Homburg/Saar, DE;
Gerd Ritter, New York, NY (US);
Achim Jungbluth, New York, NY (US);
Elisabeth Stockert, New York, NY (US);
Peter Collins, Cambridge, GB;
Webster K. Cavenee, Del Mar, CA (US);
Huei-jen Su Huang, Rancho Santa Fe, CA (US);
Antony Wilks Burgess, Camberwell, AU;
Edouard Collins Nice, St Kilda, AU;
Lloyd J. Old, New York, NY (US);
Terrance Grant Johns, Melbourne, AU;
Con Panousis, Melbourne, AU;
Andrew Mark Scott, Kew, AU;
Christoph Renner, Homburg/Saar, DE;
Gerd Ritter, New York, NY (US);
Achim Jungbluth, New York, NY (US);
Elisabeth Stockert, New York, NY (US);
Peter Collins, Cambridge, GB;
Webster K. Cavenee, Del Mar, CA (US);
Huei-Jen Su Huang, Rancho Santa Fe, CA (US);
Antony Wilks Burgess, Camberwell, AU;
Edouard Collins Nice, St Kilda, AU;
Abbott Laboratories Inc., Abbott Park, IL (US);
Abstract
The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.